Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

TriSalus Life Sciences (TLSI) Preferred Shares Issued (2022 - 2023)

TriSalus Life Sciences has reported Preferred Shares Issued over the past 2 years, most recently at $5000.0 for Q3 2023.

For Q3 2023, Preferred Shares Issued changed N/A year-over-year to $5000.0; the TTM value through Jun 2024 reached $5000.0, changed N/A, while the annual FY2023 figure was $9.2 million, 31.93% down from the prior year.
Preferred Shares Issued for Q3 2023 was $5000.0 at TriSalus Life Sciences, down from $6.0 million in the prior quarter.
Over five years, Preferred Shares Issued peaked at $10.0 million in Q4 2022 and troughed at $5000.0 in Q3 2023.